Novabay Shares Tank on Impetigo Phase IIb Miss

Novabay Pharmaceuticals Inc. took a pounding in the stock market Thursday after it reported the failure of a Phase IIb study of its impetigo candidate, auriclosene. The study showed that the drug was safe and well tolerated but did not meet the primary clinical endpoint of the trial.